Results 271 to 280 of about 24,516 (282)

Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial

Lancet Neurology, The, 2018
Satoshi Kuwabara, Yasunori Sato, Nobuko Yamaguchi   +2 more
exaly  

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

Nature Reviews Nephrology, 2012
Julien Zuber, Lubka T Roumenina
exaly  

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial

American Journal of Kidney Diseases, 2016
Fadi Fakhouri, Josep M Campistol, Spero R Cataland   +2 more
exaly  

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

Kidney International, 2016
Larry A Greenbaum, Gianluigi Ardissino, Lars Pape   +2 more
exaly  

Systemic Complement Inhibition with Eculizumab for Geographic Atrophy in Age-Related Macular Degeneration

Ophthalmology, 2014
Giovanni Gregori, Kang Zhang, Srinivas R Sadda   +2 more
exaly  

Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

British Journal of Haematology, 2013
Peter Hillmen, Alexander Röth, Hubert Schrezenmeier   +2 more
exaly  

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

Blood, 2008
Robert A Brodsky, Hubert Schrezenmeier, Peter Hillmen   +2 more
exaly  

Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival

Blood, 2011
Stephen J Richards, Peter Hillmen
exaly  

Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

Arthritis and Rheumatism, 2012
Danieli Castro O Andrade, Steven L Allen
exaly  

Eculizumab for paroxysmal nocturnal haemoglobinuria

Lancet, The, 2009
exaly